Apitope hires Dr. Graham Roberts as Development Director for Therapeutics
Apitope International N.V. announced the appointment of Dr. Graham Roberts as Development Director for Therapeutics. Among his responsibilities at Apitope, Dr Roberts will have overall responsibility for Apitope's R&D activities with an initial focus on the ATX-MS-1467 project. In January, Apitope signed a development and commercialization deal with Merck Serono to develop ATX-MS-1467, a targeted approach to treat multiple sclerosis.
Dr. Roberts joins Apitope from SRA GCD Ltd (formerly, Constella Group Ltd), which he joined in 2004 and was promoted to Global VP of Regulatory Affairs & Strategic Drug Development Services in early 2009.
Dr. Roberts will be reporting directly to Dr. Martin and will also work on advancing Apitope's growing portfolio in other autoimmune diseases areas.
From 1991 to 2004, Dr. Roberts worked with British Biotech in a number of roles; latterly as Project Director & Biologics Manufacturing Manager. Earlier, he was a Group Manager within research at Celltech Group. Dr. Roberts obtained his PhD. in the Biochemistry Department at the University of Cambridge.
Other news from the department people
